Validation of Recombinant Type I Interferon Antiviral Activity Against Porcine Epidemic Diarrhea Virus In Vitro and...

Porcine epidemic diarrhea virus (PEDV), a coronavirus responsible for severe watery diarrhea in neonatal piglets, leads to significant economic losses globally. Effective prevention and treatment of PEDV infection is critical to the swine industry. Currently, there are no available therapeutic drugs for PEDV. Porcine interferons (poIFNs) have been identified as promising molecules against a series of swine viruses due to their broad-spectrum antiviral and immunomodulatory properties. In this study, we demonstrated that type I interferon-α (IFN-α) offered both prophylactic and therapeutic benefits against PEDV infection. Recombinant poIFN-α produced by a prokaryotic expression system was purified through affinity chromatography, and its prophylactic and therapeutic effects against PEDV infection were evaluated in vitro and in vivo through RT-qPCR, clinical symptom monitoring, and pathological examination. In vitro studies revealed a strong antiviral activity of poIFN-α against PEDV in Vero E6 cells, with a more pronounced prophylactic effect compared to therapeutic outcomes. In vivo studies showed that poIFN-α significantly alleviated clinical diarrhea in PEDV-infected piglets and reduced intestinal viral loads. These findings suggest that poIFN-α holds considerable promise as an antiviral agent for PEDV and provides a foundation for the development of therapeutic strategies targeting this virus.